---
title: "RXRX.US (RXRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RXRX.US/news.md"
symbol: "RXRX.US"
name: "RXRX.US"
parent: "https://longbridge.com/en/quote/RXRX.US.md"
datetime: "2026-05-21T01:47:05.655Z"
locales:
  - [en](https://longbridge.com/en/quote/RXRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RXRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RXRX.US/news.md)
---

# RXRX.US (RXRX.US) — Related News

### [Tian Yuandong's AI startup is valued at 31.5 billion, with investments from Lao Huang and Su Ma](https://longbridge.com/en/news/286363524.md)
*2026-05-14T05:44:05.000Z*
> The AI company Recursive Superintelligence (RSI), founded by Tian Yuandong, has secured $650 million in funding, reachin

### [Lin Junyang: 2 billion, Tian Yuandong et al.: 4.65 billion](https://longbridge.com/en/news/286360902.md)
*2026-05-14T05:05:51.000Z*
> On May 13th, the AI Lab startup activities in both China and the United States attracted attention again. Lin Junyang, t

### [3 Stocks Poised to Disrupt the Healthcare Market by 2030](https://longbridge.com/en/news/285719882.md)
*2026-05-08T12:00:19.000Z*
> Three companies are set to disrupt the healthcare market by 2030: Tempus AI, Recursion Pharmaceuticals, and Axsome Thera

### [Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back](https://longbridge.com/en/news/285591265.md)
*2026-05-07T17:04:59.000Z*
> Recursion Pharmaceuticals is set to update on the FDA trial design for its drug REC-4881 for familial adenomatous polypo

### [Recursion Pharmaceuticals Q1 Earnings Call Highlights](https://longbridge.com/en/news/285435745.md)
*2026-05-06T20:42:50.000Z*
> Recursion Pharmaceuticals (NASDAQ: RXRX) emphasized its focus on AI-driven drug discovery during its Q1 earnings call. C

### [Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings Results](https://longbridge.com/en/news/285426494.md)
*2026-05-06T19:48:24.000Z*
> Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly earnings of ($0.22) EPS, surpassing estimates of ($0.30) by $

### [Recursion Reports First Quarter Financial Results and Provides Business Update](https://longbridge.com/en/news/285358809.md)
*2026-05-06T10:30:00.000Z*
> Recursion reported its first quarter financial results, highlighting significant progress in its clinical pipeline. Key 

### [Recursion Pharmaceuticals | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 6.472 M](https://longbridge.com/en/news/285356809.md)
*2026-05-06T10:34:32.000Z*